Share this:
January 19th, 2017

Researchers identify new drug target for gastrointestinal stromal tumors

By Sharon Rosen

Article by Colette Gallagher, Public Affairs

Dr. Tamas Ordog

Tamas Ordog, M.D., director of the Epigenomics Program at the Mayo Clinic Center for Individualized Medicine, and Jason Sicklick, M.D., of UC San Diego Health, identified a new drug target for gastrointestinal stromal tumors.

Gastrointestinal stromal tumors (GIST) are the most common sarcoma with an estimated annual incidence of 6.8 cases per million people in the United States. These tumors start in special cells found in the wall of the GI tract, called the interstitial cells of Cajal (ICC). ICC are sometimes called the “pacemakers” of the GI tract because they signal the muscles in the digestive system to contract to move food and liquid through the GI tract. Dr. Ordog is a basic scientist known for his research on ICC.

According to Dr. Ordog their finding may help overcome resistance to currently available medical therapy, a problem more than 95 percent of GIST patients eventually face, by using a drug already used in clinical practice.

Read more.

Learn more about precision medicine and join our community

Get the latest news from the Center for Individualized Medicine. Visit our blogFacebookLinkedIn or Twitter at @MayoClinicCIM.

Save the date for the next Individualizing Medicine Conference on  Oct. 9-11, 2017.

 

Tags: #Dr. Tamas Ordog, #drug target, #Gastrointestinal stromal tumors, #GI cancer, #GIST, center for individualized medicine, mayo clinic, medical research, sarcoma, Uncategorized

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy